| Literature DB >> 31413793 |
Christopher J Helal1, Mark Bundesmann1, Susan Hammond1, Melissa Holmstrom2, Jacquelyn Klug-McLeod1, Bruce A Lefker3, Dale McLeod1, Chakrapani Subramanyam1, Oleg Zakaryants4, Sylvie Sakata2.
Abstract
Many pharmaceutical companies have invested millions of dollars in establishing internal chemical stores to provide reliable access to large numbers of building blocks (BB) for the synthesis of new molecules, especially for the timely design and execution of parallel (library) synthesis. Recognizing budget and logistical limitations, we required a more economically scalable process to provide diverse BB. We disclose a novel business partnership that achieves the goals of just-in-time, economical access to commercial BB that increases chemical space coverage and accelerates the synthesis of new drug candidates. We believe that this model can be of benefit to companies of all sizes that are engaged in drug discovery by reducing cost, increasing diversity of analog molecules in a time-conscious manner, and reducing BB inventory. More efficient use of BB by customers may allow commercial vendors to devote a greater portion of their resources to preparing novel BB that increase chemical diversity as opposed to resynthesizing out-of-stock compounds that are inaccessible within company compound collections.Entities:
Year: 2019 PMID: 31413793 PMCID: PMC6691476 DOI: 10.1021/acsmedchemlett.9b00205
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345